期刊文献+

阿托伐他汀关键中间体的合成工艺优化

Synthesis Process Optimization of the Atorvastatin Key Intermediate
下载PDF
导出
摘要 以对氟苯甲醛和4-甲基-3-氧-N-苯-2-(苯亚甲基)戊酰胺为起始原料,噻唑溴化物和三乙胺作为催化剂,通过Stetter反应合成阿托伐他汀关键中间体2-[2-(4-氟苯基)-2-氧代-1-苯基乙基]-4-甲基-3-氧代-N-苯基戊酰胺。根据可能的反应机理,从质子、非质子溶剂和不同极性大小的溶剂中寻找合适的溶剂提高Stetter反应收率和产品质量。研究了溶剂类型、反应温度、溶剂用量、催化剂种类和反应时间等因素对反应的影响,得到的优化工艺条件为:以四氢呋喃作为反应溶剂,用量为原料质量的2.7倍,以溴化3-乙基-5-(2-羟基乙基)-4-甲基噻唑和三乙胺作为催化剂,在65℃下反应16h。在上述条件下,阿托伐他汀关键中间体2-[2-(4-氟苯基)-2-氧代-1-苯基乙基]-4-甲基-3-氧代-N-苯基戊酰胺的纯度大于99.5%,收率高于88%,产品质量和收率大幅提高,明显减少了脱氟杂质(Des-fluoro)及其他副反应,有利于提高产品的竞争力。 The atorvastatin key intermediate,2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-N-phenylpentanamide,was synthesized by Stetter reaction using p-fluorophenaldehyde and(Z)-2-benzylidene-4-methyl-3-oxo-N-phenylpentanamide as starting materials and thiazolium bromide and triethylamine as catalysts.According to the possible reaction mechanism,suitable solvents were searched from protic or aprotic solvent,and solvents of different polarity to improve Stetter reaction yield and product quality.The effects of solvent type,reaction temperature,solvent dosage,catalyst type and reaction time on the reaction were studied,the optimized conditions were as follows:tetrahydrofuran as the reaction solvent,the amount was 2.7 times mass ratio that of 2-benzylidene-4-methyl-3-oxo-N-phenylpentanamide,3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide and triethylamine as the catalysts,and the reaction time was 16 hours at 65.Under the℃above conditions,the purity of the atorvastatin key intermediate,2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-N-phenylpentanamide was above 99.5%,and the yield was above 88%,which greatly improved the product quality and yield,and reduced Des-fluoro impurity and other side reactions.It is beneficial to improve the competitiveness of products.
作者 陈伟荣 吕志卿 周刚 肖玉峰 王宇 CHEN Weirong;LV Zhiqing;ZHOU Gang;XIAO Yufeng;WANG Yu(Zhejiang Hisoar Chuannan Pharmaceutical Company Limited,Taizhou 317000,China)
出处 《化学反应工程与工艺》 CAS 2023年第2期145-151,共7页 Chemical Reaction Engineering and Technology
关键词 Stetter反应 极性非质子溶剂 亲核试剂 四氢呋喃 Stetter reaction polar aprotic solvent nucleophile tetrahydrofuran
  • 相关文献

参考文献4

二级参考文献18

  • 1陈修 陈维洲 等.心血管药理学,第二版[M].北京:人民卫生出版社,1997.514. 被引量:4
  • 2-.-[J].有机氟工业,1997,(3):21-21. 被引量:1
  • 3-.-[J].中国医药工业杂志,1997,28(8):376-376. 被引量:1
  • 4[1]Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia[J]. Drugs 1996; 51: 433-59. 被引量:1
  • 5[2]Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis 1996; 119: 203-13. 被引量:1
  • 6[3]Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase[J]. Am J Cardiol 1994; 73 Suppl D: 3D-11D. 被引量:1
  • 7[4]Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[J]. JAMA 1996; 275: 128-33. 被引量:1
  • 8[5]Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease[J]. Drugs 1997; 53: 299-336. 被引量:1
  • 9[6]Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation[J]. Atherosclerosis 1994; 111: 127-42. 被引量:1
  • 10[7]Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J]. Drugs 1997; 53: 828-47. 被引量:1

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部